These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1419 related items for PubMed ID: 17198079

  • 1. A clinical development paradigm for cancer vaccines and related biologics.
    Hoos A, Parmiani G, Hege K, Sznol M, Loibner H, Eggermont A, Urba W, Blumenstein B, Sacks N, Keilholz U, Nichol G, Cancer Vaccine Clinical Trial Working Group.
    J Immunother; 2007 Jan; 30(1):1-15. PubMed ID: 17198079
    [Abstract] [Full Text] [Related]

  • 2. Design of clinical trials for therapeutic cancer vaccines development.
    Mackiewicz J, Mackiewicz A.
    Eur J Pharmacol; 2009 Dec 25; 625(1-3):84-9. PubMed ID: 19835869
    [Abstract] [Full Text] [Related]

  • 3. Cancer vaccines: clinical development challenges and proposed regulatory approaches for patient access to promising treatments.
    Stebbing J, Wood C, Atkins M, Bukowski R, Litwin S, Bower M, Parsa A, Levitsky H.
    Cancer; 2008 Mar 01; 112(5):955-61. PubMed ID: 18286505
    [Abstract] [Full Text] [Related]

  • 4. Lessons learned from independent central review.
    Ford R, Schwartz L, Dancey J, Dodd LE, Eisenhauer EA, Gwyther S, Rubinstein L, Sargent D, Shankar L, Therasse P, Verweij J.
    Eur J Cancer; 2009 Jan 01; 45(2):268-74. PubMed ID: 19101138
    [Abstract] [Full Text] [Related]

  • 5. Current vaccination strategies for prostate cancer.
    Joniau S, Abrahamsson PA, Bellmunt J, Figdor C, Hamdy F, Verhagen P, Vogelzang NJ, Wirth M, Van Poppel H, Osanto S.
    Eur Urol; 2012 Feb 01; 61(2):290-306. PubMed ID: 22001436
    [Abstract] [Full Text] [Related]

  • 6. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J, Puech A, Boissel JP, Participants inRound Table No 7, Giens XXII.
    Therapie; 2007 Feb 01; 62(5):427-35. PubMed ID: 18206104
    [Abstract] [Full Text] [Related]

  • 7. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H, Namba K.
    Kekkaku; 2006 Dec 01; 81(12):753-74. PubMed ID: 17240921
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Potency assays for therapeutic live whole cell cancer vaccines.
    Petricciani J, Egan W, Vicari G, Furesz J, Schild G.
    Biologicals; 2007 Apr 01; 35(2):107-13. PubMed ID: 16882459
    [Abstract] [Full Text] [Related]

  • 10. A phased approach to clinical testing: criteria for progressing from Phase I to Phase II to Phase III studies.
    André FE, Foulkes MA.
    Dev Biol Stand; 1998 Apr 01; 95():57-60. PubMed ID: 9855414
    [Abstract] [Full Text] [Related]

  • 11. Gd-Tex Pharmacyclics Inc.
    Radford IR.
    Curr Opin Investig Drugs; 2000 Dec 01; 1(4):524-8. PubMed ID: 11249709
    [Abstract] [Full Text] [Related]

  • 12. Molecular imaging of antiangiogenic agents.
    Rehman S, Jayson GC.
    Oncologist; 2005 Feb 01; 10(2):92-103. PubMed ID: 15709211
    [Abstract] [Full Text] [Related]

  • 13. [Novel vaccines against M. tuberculosis].
    Okada M.
    Kekkaku; 2006 Dec 01; 81(12):745-51. PubMed ID: 17240920
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Preventive HIV type 1 vaccine clinical trials: a regulatory perspective.
    Goldenthal KL, Vaillancourt JM, Geber A, Lucey DR.
    AIDS Res Hum Retroviruses; 1998 Oct 01; 14 Suppl 3():S333-40. PubMed ID: 9814962
    [Abstract] [Full Text] [Related]

  • 17. Towards therapeutic vaccines for colorectal carcinoma: a review of clinical trials.
    Mosolits S, Nilsson B, Mellstedt H.
    Expert Rev Vaccines; 2005 Jun 01; 4(3):329-50. PubMed ID: 16026248
    [Abstract] [Full Text] [Related]

  • 18. Vaccine therapy in patients with renal cell carcinoma.
    Van Poppel H, Joniau S, Van Gool SW.
    Eur Urol; 2009 Jun 01; 55(6):1333-42. PubMed ID: 19201522
    [Abstract] [Full Text] [Related]

  • 19. Dendritic cell vaccines in melanoma: from promise to proof?
    Lesterhuis WJ, Aarntzen EH, De Vries IJ, Schuurhuis DH, Figdor CG, Adema GJ, Punt CJ.
    Crit Rev Oncol Hematol; 2008 May 01; 66(2):118-34. PubMed ID: 18262431
    [Abstract] [Full Text] [Related]

  • 20. [Current status and future perspective of cancer vaccine development].
    Sasada T, Itoh K.
    Gan To Kagaku Ryoho; 2011 Apr 01; 38(4):503-8. PubMed ID: 21498975
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 71.